Merrimack Pharmaceuticals Stock Market Capitalization
| MACKDelisted Stock | USD 11.96 0.12 1.01% |
Merrimack Pharmaceuticals fundamentals help investors to digest information that contributes to Merrimack Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Merrimack Stock. The fundamental analysis module provides a way to measure Merrimack Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merrimack Pharmaceuticals stock.
Merrimack |
Merrimack Pharmaceuticals Company Market Capitalization Analysis
Merrimack Pharmaceuticals' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Merrimack Pharmaceuticals Market Capitalization | 223.75 M |
Most of Merrimack Pharmaceuticals' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merrimack Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
CompetitionBased on the recorded statements, the market capitalization of Merrimack Pharmaceuticals is about 223.75 M. This is 98.27% lower than that of the Biotechnology sector and 95.28% lower than that of the Health Care industry. The market capitalization for all United States stocks is 98.82% higher than that of the company.
Merrimack Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merrimack Pharmaceuticals' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics of similar companies.Merrimack Pharmaceuticals is currently under evaluation in market capitalization category among its peers.
Merrimack Fundamentals
| Return On Equity | -0.0112 | |||
| Return On Asset | -0.0107 | |||
| Current Valuation | (20.36 M) | |||
| Shares Outstanding | 14.79 M | |||
| Shares Owned By Insiders | 1.19 % | |||
| Shares Owned By Institutions | 62.97 % | |||
| Number Of Shares Shorted | 842.49 K | |||
| Price To Earning | 65.70 X | |||
| Price To Book | 11.38 X | |||
| Gross Profit | (9.1 M) | |||
| EBITDA | (2.18 M) | |||
| Net Income | (1.18 M) | |||
| Cash And Equivalents | 13.36 M | |||
| Cash Per Share | 1.00 X | |||
| Debt To Equity | 33.90 % | |||
| Current Ratio | 31.85 X | |||
| Book Value Per Share | 15.25 X | |||
| Cash Flow From Operations | (1.52 M) | |||
| Short Ratio | 8.65 X | |||
| Earnings Per Share | (0.09) X | |||
| Price To Earnings To Growth | 0.07 X | |||
| Target Price | 4.0 | |||
| Beta | 1.42 | |||
| Market Capitalization | 223.75 M | |||
| Total Asset | 19.19 M | |||
| Retained Earnings | (548.82 M) | |||
| Working Capital | 18.74 M | |||
| Current Asset | 89.62 M | |||
| Current Liabilities | 88.28 M | |||
| Net Asset | 19.19 M |
About Merrimack Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Merrimack Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merrimack Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merrimack Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |